Header graphic for print
Dangerous Drugs & Medical Devices News & Commentary on Prescription Drug & Medical Device Lawsuits

Humira Lawsuit Information

Humira® Lawsuit Information

Humira® (Adalimumab) is an anti-inflammatory medication in family of tumor necrosis factor (TNF) inhibitors, drugs that kill TNF cells that cause inflammation.  Humira® was originally approved by the United States Food and Drug Administration in December, 2002 for the reduction of pain-causing inflammation in conditions such as ankylosing spondylitis, rheumatoid arthritis, plaque psoriasis, juvenile idiopathic arthritis, psoriatic arthritis, and most recently, Crohn’s Disease.

While studies have found the drug to be effective in limiting inflammation caused by these diseases, contemporary research has shown that use of Humira® may dramatically raise the risk of serious infection and malignancy in some users.

Humira® and Infection

For example, a study published in The Medical Journal of Australia by Kaspar Wilson et al. in August of 2012 showed a direct association between listeria monocytogenes infection and use of Humira®.  Furthermore, medical researchers Saane van Dartel et al (2012) have demonstrated that Humira® use raises the risk of serious infection by a factor of 3.86, compared with other less dangerous medications.

Humira® and Malignancy

Recently, the risk for malignancy among users of Humira® has become cause for concern.  Prominent prescription drug information website www.rxlist.com cites an emerging risk for lymphoma and other cancers associated with Humira® use, writing that “these cases have had a very aggressive disease course and have been fatal,” affecting both children and adults alike.

Humira® Infection Lawsuits and Humira® Malignancy Lawsuits

The most serious complications associated with Humira® use are serious infections and the growth of malignant tumors in some people. Though the manufacturer of Humira® – Abbott Laboratories –suggests that infections and cases of lymphoma or other malignancies caused by Humira® use are rare occurrences, the medical reports cited above, along with others similar suggest otherwise.

As is always the case, the manufacturer of Humira® is legally obligated to make clear warnings about all complications associated with the use of its products, and advise users about the likelihood that those complications should occur.  Any withholding of information from the consumer or misleading of the customer by the manufacturer is criminal, and when situations like this do occur, manufacturers must be held responsible for their actions or lack thereof.

Due to the emerging and increasingly-clear fact that the likelihood of serious complications occurring with Humira® use is significantly higher than is reported by Abbott Laboratories, people who used Humira® and suffered a serious infection or malignancy may be eligible to file a Humira® lawsuit.

More Information on Humira®

If you have a question about Humira® that isn’t answered here, feel free to give my office a call at (855) 452 – 5529 or e-mail me at justinian@dangerousdrugs.us.

Also, every post we’ve written about Humira is available here.